CSL Ltd (CSL AU): Double-Digit Sales and Profit Growth in H1FY24 Led by Immunoglobulin Franchise
In H1FY24, CSL reported 23% YoY growth in revenue from Immunoglobulin. The company has reaffirmed FY24 guidance. FY24 revenue and NPATA are...
235 Views
CSL Ltd (CSL AU): Banking on Strong Growth in Immunoglobulin Franchise on Record Plasma Collection
In FY23, plasma volume grew 31%, while plasma collection cost declined ~14% YoY and down 17% from the peak. In FY24, revenue and profit are...
444 Views
CSL Ltd (CSL AU): FY23 Guidance Cut Drags Near-Term Prospect; Long-Term Growth Drivers Still Intact
CSL reduced FY23 profit projection due to higher-than-anticipated Fx headwind of $230–250M from $175M. Strong demand for existing products and new...
361 Views
Australia Short Interest (Q1 2024): A Recap
Total short interest in Australia is A$34.46bn and has decreased by A$1.36bn since the start of the year. We look at the stocks with the largest...
326 Views
ASX Short Interest Weekly (Mar 22nd): Rio Tinto, Webjet, Xero, CSL, Westpac, Macquarie
We analyzed ASX short interest report for the past week and highlight short interest changes in Rio Tinto, Webjet, Xero, CSL, Westpac, Macquarie,...
473 Views